Understanding Abdominal Pain in IBD and IBS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-20

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Abdominal pain is a central symptom of Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS). IBD is an autoimmune disease characterized by inflammation of the gastrointestinal tract. IBS does not have clear biomarkers and is diagnosed based on symptom reports. The aim of this study is to explore biopsychosocial factors which may perpetuate and/or increase the severity of pain in these conditions. The main focus will be on the role of top-down brain processes in the experience of abdominal pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phenotyping IBS: Perceptions and Modulations of Visceral Sensations

NCT02693730

Irritable Bowel Syndrome Ulcerative Colitis Inflammatory Bowel Disease

COMPLETED

Brain-Gut Interactions in Overweight and Normal Weight Patients With Chronic Abdominal Pain

NCT00824941

Obesity Stress Irritable Bowel Syndrome +2 more

TERMINATED

The Role of Intestinal Inflammation in Irritable Bowel Syndrome (IBS)

NCT01072903

Inflammation Colon, Irritable Colonic Diseases, Functional +1 more

COMPLETED

Investigation of Acupoint in Irritable Bowel Syndrome Based on Biological Characteristics

NCT06365801

Irritable Bowel Syndrome

NOT_YET_RECRUITING

Small and Large Bowel Transit Tests Using MRI (Study 1)

NCT01534507

Irritable Bowel Syndrome

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It remains unclear why a large proportion of people with inflammatory bowel disease (IBD) report ongoing abdominal pain during remission or why people with irritable bowel syndrome (IBS) develop abdominal pain. One theory is that people with chronic pain have somehow grown more sensitive.

It is assumed that such heightened sensitivity depends both on bottom-up processing and top-down processing. Bottom-up processing refers to information that is relayed to the brain along so-called afferent fibres. Top-down processing refers to feedback provided by the brain to lower areas along efferent fibres.

The investigators will (1) measure the capacity of people to inhibit pain through top-down processing, (2) test if the human pain experience is enhanced due to sustained activation of certain afferents, and (3) assess to what extent people are impacted by psychosocial inhibition and activation factors. Results of people with IBS in remission will be compared with the results of two groups of people with IBD (those with pain and those without) and the investigators will explore if their measurements differentiate between groups.

It is hypothesized that (1) IBS patients and IBD patients with abdominal pain will be less able to inhibit their pain compared to IBD patients without abdominal pain (2) IBS patients and IBD patients with abdominal pain will score higher on psychosocial inhibition factors and lower on psychosocial activation factors when compared to IBD patients without abdominal pain. (3) In the total cohort, laboratory measures of pain inhibition will correlate with self-reported psychosocial inhibition and activation factors. (4) IBS patients and IBD patients with abdominal pain will show more temporal summation compared to IBD patients without abdominal pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Abdominal Pain Inflammatory Bowel Diseases Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 and over
* Sufficient command of written and spoken English

* Proof of diagnosis of IBD (Crohn's disease or ulcerative colitis) for more than 6 months - - Clear indicators of remission: on faecal calprotectin (≤200 µg/g) or measurements of C-reactive protein (CRP; ≤10 mg/dl) within the last 3 months or as part of recruitment
* No previous episodes of acute or sub-acute obstruction

* Current diagnosis of IBS measured with Rome IV criteria
* No serious other bowel diseases

Exclusion Criteria

* Major abdominal surgery in the last 6 months, or 3 or more previous major abdominal surgeries
* Pregnancy or childbirth in the last 6 months
* Any other diagnosed medical condition that may explain abdominal pain, including but not limited to known gynaecological conditions such as endometriosis and known post-surgical adhesions
* Any diagnosed co-morbid medical conditions associated with known neuropathy, such as diabetic neuropathy, renal neuropathy, multiple sclerosis
* Use of opioids in the last week
* Use of anti-depressants used as pain medication in the last month

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No